论文部分内容阅读
我科自1983年7月～1996年7月共收治住院的ML病人88例，其中男性60例，女性28例，年龄0．5～80岁，中位年龄为42岁。何杰金病（HD）7例，非何杰金淋巴瘤（NHL）81例。与本校综合医院1992年以后同期收治的ML病人比较，颌面颈部ML病人占10．7％～23．6％。39例病人接受综合治疗，33例接受单纯化疗。随访病人存活时间超过7年者7例，超过5年者9例。存活病人中以临床Ⅰ、Ⅱ期者占绝大多数，而死亡病人中以Ⅲ、Ⅳ期居多。死亡病人平均存活23．6月（4～55个月），中位存活时间为12个月。研究结果提示：1．颁面颈部ML发病有明显增长趋势，应引起足够重视。2．对颌面颈部诊断不明的包块应不惜反复活检以确定诊断，特别是对T系ML。3．以化疗为主的综合治疗仍是有效的主要手段。4．临床分期对估计预后有重要的参考价值。
In our department from July 1983 to July 1996, 88 cases of ML patients were admitted to the hospital, including 60 males and 28 females, aged 0.5 to 80 years, and the median age was 42 years. There were 7 cases of Hodgkin’s disease (HD) and 81 cases of non-Hodgkin’s lymphoma (NHL). Compared with patients with ML who were admitted to the general hospital in the same period after 1992, patients with ML in the maxillofacial region accounted for 10.7% to 23.6%. Thirty-nine patients received comprehensive treatment and 33 received chemotherapy alone. Follow-up patients survived more than 7 years in 7 cases, more than 5 years in 9 cases. Among the surviving patients, the majority of patients with clinical stages I and II accounted for the majority of the patients, while those who died were mostly stage III and IV. The average number of surviving patients was 23.6 months (4 to 55 months), and the median survival time was 12 months. Research results suggest: 1. There was a significant increase in the incidence of face and neck ML, which should be given sufficient attention. 2. Undiagnosed masses in the maxillofacial and neck area should not hesitate to repeat biopsy to confirm the diagnosis, especially for T-line ML. 3. Comprehensive treatment based on chemotherapy is still the main effective method. 4. Clinical staging has important reference value for estimating prognosis.